Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 versus BCG in newborn infants for prevention of Mycobacterium tuberculosis infection
PACTR202007868402718Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- Oct 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3 trial of VPM1002 and BCG SII in Tuberculosis (TB) (2 arms), sponsored by Serum Institute of India. Started Oct 2020; status: completed.
02
Drugs
VPM1002BCG SII
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202007868402718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007868402718.